

Beat **Statement Pursuant to the Pink Basic Disclosure Guidelines**

Premier Biomedical, Inc. (the publicly traded company now Premier Holding Corp., following the holding company reorganization the announcement of which to be pursued with FINRA)

A Colorado Corporation

20750 Civic Center Drive, Suite 418, Southfield MI 48076

248 763 3203

<https://www.premierbiomedical.com>
support@premierbiomedical.com

SIC Code: 2836

Quarterly Report
For the Period Ending: June 30, 2022
(the "Reporting Period")

As of June 30, 2022, the number of shares outstanding of our Common Stock was: 999,980,958

As of March 31, 2021, the number of shares outstanding of our Common Stock was: 999,980,958

As of December 31, 2021, the number of shares outstanding of our Common Stock was: 999,980,958

Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933 and Rule 12b-2 of the Exchange Act of 1934):

Yes: ☐ No: ☒

Indicate by check mark whether the company's shell status has changed since the previous reporting period:

Yes: ☐ No: ☒

Indicate by check mark whether a Change in Control¹ of the company has occurred over this reporting period:

¹ "Change in Control" shall mean any events resulting in:

(i) Any "person" (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becoming the "beneficial owner" (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company's then outstanding voting securities;

(ii) The consummation of the sale or disposition by the Company of all or substantially all of the Company's assets;

(iii) A change in the composition of the Board occurring within a two (2)-year period, as a result of which fewer than a majority of the directors are directors immediately prior to such change; or

Yes: ☐ No: ☒

1) Name and address(es) of the issuer and its predecessors (if any)

In answering this item, provide the current name of the issuer any names used by predecessor entities, along with the dates of the name changes.

Premier Biomedical, Inc. was incorporated in the State of Nevada on May 10, 2010 ("Inception"). The Company was formed to develop and market medications and procedures that address a significant number of the most highly visible health issues currently affecting mankind. Our current focus is primarily on the development and distribution of our pain products. Pursuant to a holding company reorganization of August 2020, the publicly traded company became Premier Holding Corp. ("the Company").

The state of incorporation or registration of the issuer and of each of its predecessors (if any) during the past five years; Please also include the issuer's current standing in its state of incorporation (e.g. active, default, inactive):

Premier Biomedical, Inc., was incorporated in 2010. Premier Holding Corp., the successor issuer, was incorporated August 14, 2020.

Describe any trading suspension orders issued by the SEC concerning the issuer or its predecessors since inception:

OTC Markets has issued a 'Stop' sign on our trading, as we filed a Form 15-12G with the Securities & Exchange Commission on June 15, 2021

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

None

The address(es) of the issuer's principal executive office:

20750 Civic Center Drive, Suite 418, Southfield MI 48076

The address(es) of the issuer's principal place of business:

Check box if principal executive office and principal place of business are the same address: ☒

Has the issuer or any of its predecessors been in bankruptcy, receivership, or any similar proceeding in the past five years?

Yes: ☐ No: ☒

If this issuer or any of its predecessors have been the subject of such proceedings, please provide additional details in the space below:

N/A

(iv) The consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation.

2) Security Information

Trading symbol:	<u>BIEI</u>		
Exact title and class of securities outstanding:	<u>Common</u>		
CUSIP:	<u>74048K203</u>		
Par or stated value:	<u>\$0.00001</u>		
Total shares authorized:	<u>1,000,000,000</u>	as of date:	<u>June 30, 2022</u>
Total shares outstanding:	<u>999,980,958</u>	as of date:	<u>June 30, 2022</u>
Number of shares in the Public Float ² :	<u>999,980,958</u>	as of date:	<u>June 30, 2022</u>
Total number of shareholders of record:	<u>122</u>	as of date:	<u>June 30, 2022</u>

All additional class(es) of publicly traded securities (if any):

Trading symbol:	<u>BIEI</u>	
Exact title and class of securities outstanding:	<u>Series A Convertible Preferred</u>	
CUSIP:	<u>N/A</u>	
Par or stated value:	<u>\$0.001</u>	
Total shares authorized:	<u>10,000,000</u>	as of date: <u>June 30, 2022</u>
Total shares outstanding:	<u>2,000,000</u>	as of date: <u>June 30, 2022</u>

Trading symbol:	<u>BIEI</u>	
Exact title and class of securities outstanding:	<u>Series B Convertible Preferred</u>	
CUSIP:	<u>N/A</u>	
Par or stated value:	<u>\$0.001</u>	
Total shares authorized:	<u>1,000,000</u>	as of date: <u>June 30, 2022</u>
Total shares outstanding:	<u>133,780</u>	as of date: <u>June 30, 2022</u>

Transfer Agent

Name: Issuer Direct
Phone: (919) 481-4000
Email: info@issuerdirect.com
Address: One Glenwood Ave., Suite 1001, Raleigh, NC 27603

Is the Transfer Agent registered under the Exchange Act?³ Yes: ☒ No: ☐

1) Issuance History

The goal of this section is to provide disclosure with respect to each event that resulted in any direct changes to the total shares outstanding of any class of the issuer's securities **in the past two completed fiscal years and any subsequent interim period**.

Disclosure under this item shall include, in chronological order, all offerings and issuances of securities, including debt convertible into equity securities, whether private or public, and all shares, or any other securities or options to acquire such securities, issued for services. Using the tabular format below, please describe these events.

A. Changes to the Number of Outstanding Shares

² "Public Float" shall mean the total number of unrestricted shares not held directly or indirectly by an officer, director, any person who is the beneficial owner of more than 10 percent of the total shares outstanding (a "control person"), or any affiliates thereof, or any immediate family members of officers, directors and control persons.

³ To be included in the Pink Current Information tier, the transfer agent must be registered under the Exchange Act. Check this box to indicate there were no changes to the number of outstanding shares within the past two completed fiscal years and any subsequent periods: ☒

Shares Outstanding Fiscal Year End: 12/31/20	as of Second Most Recent Opening Balance	
	Common: 999,980,958	
	Preferred:	

OTC

Date of Transaction	Transaction type (e.g. new issuance, cancellation, shares returned to treasury)	Number of Shares Issued (or cancelled)	Class of Securities	Value of shares issued (\$/per share) at Issuance	Were the shares issued at a discount to market price at the time of issuance? (Yes/No)	Individual/ Entity Shares were issued to (entities must have individual with voting / investment control disclosed).	Reason for share issuance (e.g. for cash or debt conversion) - OR- Nature of Services Provided	Restricted or Unrestricted as of this filing.	Exemption or Registration Type.

	Opening Balance	
Date 06/30/22	Common: 999,980,958	
	Preferred:	

Example: A company with a fiscal year end of December 31st, in addressing this item for its quarter ended September 30, 2020, would include any events that resulted in changes to any class of its outstanding shares from the period beginning on January 1, 2018 through September 30, 2020 pursuant to the tabular format above.

Use the space below to provide any additional details, including footnotes to the table above:

B. Debt Securities, Including Promissory and Convertible Notes

Use the chart and additional space below to list and describe all outstanding promissory notes, convertible notes, convertible debentures, **or any other debt instruments that may be converted into a class of the issuer's equity securities.**

Check this box if there are no outstanding promissory, convertible notes or debt arrangements: ☒

Date of Not Issuance	Outstanding Balance (\$)	Principal Amount at Issuance (\$)	Interest Accrued (\$)	Maturity Date	Conversion Terms (e.g. pricing mechanism for determining conversion of instrument to shares)	Name of Noteholder (entities must have individual with voting / investment control disclosed).	Reason for Issuance (e.g. Loan, Services, etc.)
	Premier	BioMedical	(Subsidiary)		Debt & Promissory Notes		
08/08/17	\$2,209	\$50,000	\$13,244	11/30/17	Convertible into our common stock at the greater of (i) 60% of the lowest traded price over the 15 days prior to conversion or (ii) a fixed \$0.00005 per share - Liquidated damages of \$1K per day for failure to provide certs, and compensation for Buy-In on failure to timely deliver certs. - Principal & interest due upon default at 50% of the lowest traded price over the previous 15 days, and an additional interest rate equal to the lesser of 2% per month (24% per annum) or the maximum rate per applicable law.	Diamond Rock, LLC	Loan
04/24/18	\$17,364	\$30,000	\$2,936	07/31/18	Convertible into our common stock at 60% of the lowest traded price over the 15 days prior to conversion.	SEG-RedaShex, LLC	Loan
07/11/18	\$3,182	\$120,000	\$3,177	10/31/18	Convertible into our common stock at 60% of the lowest traded price over the 15 days prior to conversion.	RedDiamond Partners LLC	Loan
07/11/18	\$60,000	\$60,000	\$6,182	10/31/18	Convertible into our common stock at 60% of the lowest traded price over the 15 days prior to conversion.	SEG-RedaShex, LLC	Loan
04/17/19	\$11,044	\$51,500	\$7,540	04/17/20	Convertible into our common stock at 60% of the lowest traded price over the 20 days prior to conversion.	Crown Bridge	Loan
	\$13,756	\$38,000	\$5,098		VIII Convertible into our common stock at 61% of the avg of the two lowest closing bid prices over the 20 days prior to		Loan

					conversion.		
	\$36,050	\$36,050	\$9,731		Convertible into our common		Loan
07/02/19				06/27/20	stock at 60% of the lowest	Crown Bridge	
					traded price over the 20 days		
					prior to conversion.		
08/02/19	\$38,000	\$38,000	\$8,224	08/02/20	VIII Convertible into our common	Power Up Lending	Loan
					stock at 61% of the avg of the		
					two lowest closing bid prices		
					over the 20 days prior to		
					conversion.		
08/15/19	\$43,000	\$43,000	\$9,154	08/15/20	VIII Convertible into our common	Power Up Lending	Loan
					stock at 61% of the avg of the		
					two lowest closing bid prices		
					over the 20 days prior to		
					conversion.		
09/12/19	\$25,750	\$25,750	\$6,340	09/12/20	Convertible into our common	Crown Bridge	Loan
					stock at 60% of the lowest		
					traded price over the 20 days		
					prior to conversion.		
10/03/19	\$150,000	\$150,000	\$35,902	10/03/20	Convertible into our common	Green Coast Cap. Int'l. SA	Loan
					stock at 60% of the lowest		
					traded price over the 15 days		
					prior to conversion, less \$1,000		
					deduction from each conversion		
					to cover holder's deposit fees.		

Premier Holding Corp. (Parent) Debt & Promissory Notes

I	08/20/20/	\$ 36,539.	\$ 36,539.	\$ 10,961.70	08/20/21	Convertible to common stock.	Ronnie Godeaux	Loan / Note.	I
I.									
I									

Use the space below to provide any additional details, including footnotes to the table above:

All notes are in default, and the Company only has 19,042 unissued shares that it can issue without amending the Articles of Incorporation to increase the authorized shares.

4) Financial Statements

A. The following financial statements were prepared in accordance with:

- ☒ U.S. GAAP
☐ IFRS

B. The financial statements for this reporting period were prepared by (name of individual)⁴:

Name: Liam Tynan
Title: Accountant
Relationship to Issuer: Consultant

The Quarterly Financial Statements dated 06/30/22 are incorporated by reference as they are posted on www.otcmarkets.com

Provide the financial statements described below for the most recent fiscal year or quarter. For the initial disclosure statement (qualifying for Pink Current Information for the first time) please provide reports for the two previous fiscal years and any subsequent interim periods.

- C. Balance sheet;
- A. Statement of income;
- B. Statement of cash flows;
- C. Statement of Retained Earnings (Statement of Changes in Stockholders' Equity)
- D. Financial notes; and
- E. Audit letter, if audited

⁴ The financial statements requested pursuant to this item must be prepared in accordance with US GAAP or IFRS by persons with sufficient financial skills.

You may either (i) attach/append the financial statements to this disclosure statement or (ii) file the financial statements through OTCIQ as a separate report using the appropriate report name for the applicable period end. ("Quarterly Report," "Quarterly Report" or "Interim Report").

If you choose to publish the financial statements in a separate report as described above, you must state in the accompanying disclosure statement that such financial statements are incorporated by reference. You may reference the document(s) containing the required financial statements by indicating the document name, period end date, and the date that it was posted to OTCIQ in the field below. Financial Statements must be compiled in one document.

Financial statement information is considered current until the due date for the subsequent report (as set forth in the qualifications section above).

The Annual Financial Statements dated 03/31/22 are incorporated by reference as they are posted on www.otcm Markets.com

5) Issuer's Business, Products and Services

The purpose of this section is to provide a clear description of the issuer's current operations. In answering this item, please include the following:

B. Summarize the issuer's business operations (If the issuer does not have current operations, state "no operations") The Company is a holding company and acquisition vehicle for established businesses.

C. Please list any subsidiaries, parents, or affiliated companies.

Premier Biomedical Pain Relief, Inc, a dissolved wholly-owned subsidiary of Premier Biomedical, Inc.

D. Describe the issuers' principal products or services.

research of medical solutions.

6) Issuer's Facilities

The goal of this section is to provide a potential investor with a clear understanding of all assets, properties or facilities owned, used or leased by the issuer and the extent in which the facilities are utilized.

In responding to this item, please clearly describe the assets, properties or facilities of the issuer, give the location of the principal plants and other property of the issuer and describe the condition of the properties. If the issuer does not have complete ownership or control of the property (for example, if others also own the property or if there is a mortgage on the property), describe the limitations on the ownership.

If the issuer leases any assets, properties or facilities, clearly describe them as above and the terms of their leases. None

7) Company Insiders (Officers, Directors, and Control Persons)

The goal of this section is to provide an investor with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant or beneficial shareholders.

Using the tabular format below, please provide information, as of the period end date of this report, regarding any person or entity owning 5% or more of any class of the issuer's securities, as well as any officer, and any director of the company, or any person that performs a similar function, regardless of the number of shares they own. **If any insiders listed are corporate shareholders or entities, provide the name and address of the person(s) beneficially owning or**

controlling such corporate shareholders, or the name and contact information (City, State) of an individual representing the corporation or entity in the note section.

Name of Officer/Director or Control Person	Affiliation with Company (e.g. Officer Title /Director/Owner of more than 5%)	Residential Address (City / State Only)	Number of shares owned	Share type/class	Ownership Percentage of Class Outstanding	Note
John Maddox	CEO	20750 Civic Center Drive, Suite 418, Southfield MI 48076	None	N/A	N/A	
_____	_____	_____	_____	_____	_____	_____
_____	_____	_____	_____	_____	_____	_____

1) Legal/Disciplinary History

A. Please identify whether any of the persons or entities listed above have, in the past 10 years, been the subject of:

1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses);

None

2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such **person's involvement in any type of business, securities, commodities, or banking activities**;

None

3. A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated; or

None

4. The entry of an order by a self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such person's involvement in any type of business or securities activities.

None

- B. Describe briefly any material pending legal proceedings, other than ordinary routine litigation incidental to the business, to which the issuer or any of its subsidiaries is a party or of which any of their property is the subject. Include the name of the court or agency in which the proceedings are pending, the date instituted, the principal parties thereto, a description of the factual basis alleged to underlie the proceeding and the relief sought. Include similar information as to any such proceedings known to be contemplated by governmental authorities.

None

9) Third Party Providers

Please provide the name, address, telephone number and email address of each of the following outside providers:

Securities Counsel

Name: John Dolkart
Firm: Dolkart Law
Address 1: 100 Pine St., Suite 1250
Address 2: San Francisco, CA 94111
Phone: (619) 501-1083
Email: John@dolkartlaw.com

Name: Gary L. Blum Esq.
Firm: Law Offices of Gary L. Blum
Address 1: 3278 Wiltshire Blvd., Suite 603
Address 2: Los Angeles, CA 90010
Phone: (213) 381-7450
Email: gblum@gblumlaw.com

10) Issuer Certification

Principal Executive Officer:

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles but having the same responsibilities) in each Quarterly Report or Annual Report.

The certifications shall follow the format below:

I, John Maddox certify that:

1. I have reviewed this Quarterly disclosure statement for the Period Ending June 30,2022 of the Company;

2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and

3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

August 15, 2022

/s/ John Maddox

Principal Financial Officer:

I, John Maddox certify that:

4. I have reviewed this Quarterly disclosure statement for the Period Ending June 30, 2022 of the Company:

5. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and

6. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

August 15, 2022

/s/ John Maddox

OTC Markets Group Inc.

OTC Pink Basic Disclosure Guidelines (v3 June 24 2021)Page11 of 14